BabarBashirMDMS FACP

Oncology • Philadelphia, PA

Gastrointestinal Cancer

Thomas Jefferson University Hospital

Join to view full profile

Dr. Bashir is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bashir's full profile

Already have an account?

Office
925 Chestnut Street
Philadelphia, PA 19107

Summary

Dr. Babar Bashir is an oncologist in Philadelphia, PA and is affiliated with Thomas Jefferson University Hospitals. He received his medical degree from Quaid-e-Azam Medical College and has been in practice 10 years. He also speaks multiple languages, including Hindi, Punjabi, and Urdu. He specializes in gastrointestinal cancer and is experienced in clinical research, gastrointestinal oncology, developmental therapeutics, and translational research.

Education & Training

Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Hematology and Medical Oncology, 2017 - 2019
Sidney Kimmel Medical College at Thomas Jefferson UniversityFellowship, Clinical Pharmacology, 2016 - 2018
Thomas Jefferson UniversityMS, Pharmacology, 2015 - 2018
Abington Memorial HospitalChief Residency, Internal Medicine, 2014 - 2015
Abington Memorial HospitalResidency, Internal Medicine, 2011 - 2014
Abington Memorial HospitalInternship, Internal Medicine, 2011 - 2012
Quaid-e-Azam Medical CollegeClass of 2006

Certifications & Licensure

NJ State Medical License 2020 - 2025
PA State Medical License 2010 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma Start of enrollment: 2020 Nov 10
Suspended
Phase 2
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression Start of enrollment: 2019 Nov 07
Recruiting
Phase 1, Phase 2
A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma Start of enrollment: 2019 Dec 18
Completed
Phase 1
A Study to Investigate LYL797 in Adults With Solid Tumors Start of enrollment: 2022 Mar 29
Recruiting
Phase 1
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors Start of enrollment: 2020 Dec 13
Recruiting
Phase 1, Phase 2
A Study of DSP107 Alone and in Combination With Atezolizumab for Patients With Advanced Solid Tumors Start of enrollment: 2020 Oct 07
Recruiting
Phase 1, Phase 2
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors Start of enrollment: 2020 Jan 23
Completed
Phase 1
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery Start of enrollment: 2019 Dec 16
Active, not recruiting
Phase 2, Phase 3
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Start of enrollment: 2021 Aug 09
Recruiting
Phase 1
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors Start of enrollment: 2022 Jan 07
Active, not recruiting
Phase 1
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) Start of enrollment: 2021 Sep 13
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

6 citations
Immunotherapy resistance in solid tumors: mechanisms and potential solutions.
Daniel S Lefler, Steven A Manobianco, Babar Bashir
Cancer Biology & Therapy. 2024-12-31
Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors.
Babar Bashir, Judy S Wang, Gerald Falchook, Elisa Fontana, Hendrik-Tobias Arkenau
Journal of Clinical Oncology. 2024-10-10
Brief Report: Impact of Anti-Cancer Treatments on Outcomes of COVID-19 in Patients With Thoracic Cancers: A CCC19 Registry Analysis.
Amit A Kulkarni, Cassandra Hennessy, Grace Wilson, Vidhyalakshmi Ramesh, Clara Hwang
Clinical Lung Cancer. 2024-07-01

Press Mentions

Vaccine Combo Hits Back at Treatment-Resistant Cancer in Fight Backed by US Department of DefenseJune 23rd, 2022
Chimeric Ad5.F35 Vector Evades Anti-Adenovirus Serotype 5 Neutralization Opposing GUCY2C-Targeted Antitumor ImmunityAugust 25th, 2020
New Cancer Vaccine Is Predicted to Be More Effective in Human TrialsAugust 24th, 2020
Join now to see all